August 5, 2008
Internationally renowned prostate cancer expert Dr. Oliver Sartor has joined Tulane University School of Medicine as the new Piltz Professor of Cancer Research in the Departments of Medicine and Urology.
Sartor, one of the only medical oncologists in Louisiana, Mississippi or Arkansas specializing in the treatment of prostate cancer patients, is sought after by patients across the country because of his expertise in hard-to-treat cases and cutting-edge therapies at the forefront of cancer research. Sartor has seen patients from New Mexico, Texas, Mississippi, Alabama, North Carolina, Florida, and throughout Louisiana since his arrival at Tulane earlier this year.
“Patients come to me because I deal with difficult cases, particularly those that have failed initial therapies,” Sartor says. “However, I am increasingly being consulted on early-stage cases to help patients understand and balance the risks and benefits of their therapeutic options.”
As a leading academic in cancer treatment, Sartor is co-author of the prostate cancer chapter in the 8th edition of Cancer: Principles & Practice of Oncology, one of today’s most influential cancer texts. Sartor is also an active advocate of clinical research, and will serve as the principal investigator on a number of new prostate cancer trials set to open at Tulane, including one on abiraterone, a once-a-day pill that shows promise in shrinking tumors in men with advanced prostate cancer who had not responded to other treatments.
Sartor and his family have had many connections to Tulane over the years. He graduated from Tulane University’s School of Medicine in 1982 and completed his residency at Tulane in 1986. Sartor’s great-grandfather graduated in 1872 from what would become Tulane University School of Medicine. Sartor’s wife, Sissy, and her father are also graduates of Tulane University School of Medicine, and their son will be starting his sophomore year at the medical school this fall.
Immediately prior to joining Tulane’s faculty, Sartor was an associate professor in the Lank Center for Genitourinary Oncology at Harvard’s Dana-Farber Cancer Institute in Boston (2006-2008), and before that served as chief of Hematology-Oncology and director of the Stanley S. Scott Cancer Center at LSU Medical Center in New Orleans for eight years. Sartor is the chair-elect of the Department of Defense Prostate Cancer Integration Panel, which directs over $80 million in federal funding for prostate cancer research. He is also co-editor of the peer-reviewed Journal of Genitourinary Cancer and has published over 100 scholarly articles on prostate cancer.
For more information on Sartor, please visit http://www.som.tulane.edu/cancer/TCCnames/facs.html#osartor. For more information on the Tulane Cancer Center, visit www.tulanecancer.org and for more information on Tulane’s Department of Urology, please visit www.myprostatecancer.com.
Tulane University, New Orleans, LA 70118 504-865-5000 email@example.com